Welcome to our dedicated page for Urogen Pharma SEC filings (Ticker: URGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The UroGen Pharma Ltd. (URGN) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As an Israel-organized biotechnology issuer listed on The Nasdaq Stock Market, UroGen submits periodic and current reports that describe its financial condition, oncology pipeline, and corporate governance.
Investors can review Forms 10-K and 10-Q for detailed discussions of UroGen’s business, including its RTGel® reverse-thermal hydrogel platform, approved products for low-grade upper tract urothelial cancer and recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, and revenue from product sales. These reports also outline research and development spending on programs such as UGN-103, UGN-104, and UGN-501, along with risk factors specific to urothelial and specialty cancer drug development.
Form 8-K filings provide timely updates on material events, such as quarterly financial results, executive compensation decisions, FDA approvals, and key commercialization milestones like the assignment of a permanent HCPCS Level II J Code (J9282) for ZUSDURI. Proxy materials on Schedule 14A describe annual meeting agendas, board elections, equity incentive plans, and advisory votes on executive pay and auditor engagement.
On Stock Titan, these filings are paired with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand complex oncology, financial, and governance disclosures. Users can also access information relevant to insider and equity-related activity through compensation and equity plan discussions referenced in UroGen’s 8-K and DEF 14A filings.
Form 144 filed for UroGen Pharma Ltd. (URGN) reports a planned insider disposition.
- Securities: 5,149 ordinary shares.
- Estimated value: $97,573.55.
- Broker: Oppenheimer & Co., NASDAQ execution targeted for 28 Jul 2025.
- Total shares outstanding: 46,107,451; proposed sale equals ~0.011% of float.
- Share origin: Restricted Stock Units granted 31 Jan 2024 (10,000 units).
- Prior activity: Same seller disposed of 5,162 shares for $38,043.94 on 9 Jun 2025.
The filer certifies no undisclosed adverse information under Rule 144. Given the modest volume relative to outstanding shares, the transaction is unlikely to have a material price impact but continues a pattern of insider selling that investors may monitor.
UroGen Pharma Ltd. (URGN) – Form 144 filing. An unidentified insider has notified the SEC of an intended open-market sale of 7,522 ordinary shares through Oppenheimer & Co. on or after 28 Jul 2025. Based on the filer’s estimate, the block is worth $142,541.90, implying an indicative price of roughly $18.95 per share. The shares represent 0.016% of the company’s 46.1 million shares outstanding, a small fraction of float but still a required disclosure under Rule 144.
The shares stem from 16,500 restricted stock units granted and vested on 31 Jan 2024. The filer reports no other URGN share sales in the prior three months. The filer also certifies that no undisclosed material adverse information is known. While modest in size, the transaction flags upcoming insider liquidity and may be watched as a sentiment signal.